Posted by Michael Wonder on 31 Oct 2023
Cessation Therapeutics receives FDA fast track designation for CSX-1004 for prevention of fentanyl and fentanyl analogue overdose
31 October 2023 - If approved, CSX-1004 would be the first FDA approved therapy for prevention of fentanyl-related overdose.
Cessation Therapeutics today announced that the US FDA has granted fast track designation for CSX-1004, an investigational therapy for prevention of fentanyl-related overdose.
